Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Operating expenses:
Research and development	$ 2,823,669	$ 2,563,528	$ 7,626,982	$ 5,554,046
General and administrative	2,254,912	300,640	5,147,639	1,721,691
Total operating expenses	5,078,581	2,864,168	12,774,621	7,275,737
Loss from operations	(5,078,581)	(2,864,168)	(12,774,621)	(7,275,737)
Other income:
Interest income	20,546	25,865	102,809	67,699
Total other income	20,546	25,865	102,809	67,699
Net loss	(5,058,035)	(2,838,303)	(12,671,812)	(7,208,038)
Preferred stock dividend		(258,635)		(768,876)
Net loss applicable to common stock	(5,058,035)	(3,096,938)	(12,671,812)	(7,976,914)
Other comprehensive loss:
Foreign currency translation adjustments	(28,172)		(67,663)
Comprehensive loss	$ (5,086,207)	$ (3,096,938)	$ (12,739,475)	$ (7,976,914)
Net loss applicable to common stock per share, basic and diluted	$ (0.24)	$ (0.70)	$ (0.61)	$ (1.81)
Weighted average common shares outstanding, basic and diluted	20,867,526	4,400,000	20,810,004	4,400,000